QUALIGEN THERAPEUTICS INC (QLGN) Fundamental Analysis & Valuation

NASDAQ:QLGN • US74754R3012

Current stock price

3.21 USD
+0.17 (+5.59%)
At close:
3.2 USD
-0.01 (-0.31%)
After Hours:

This QLGN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. QLGN Profitability Analysis

1.1 Basic Checks

  • QLGN had negative earnings in the past year.
  • In the past year QLGN has reported a negative cash flow from operations.
  • In the past 5 years QLGN always reported negative net income.
  • In the past 5 years QLGN always reported negative operating cash flow.
QLGN Yearly Net Income VS EBIT VS OCF VS FCFQLGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -176.92%, QLGN is doing worse than 88.60% of the companies in the same industry.
Industry RankSector Rank
ROA -176.92%
ROE N/A
ROIC N/A
ROA(3y)-278.66%
ROA(5y)-298%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
QLGN Yearly ROA, ROE, ROICQLGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

  • QLGN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
QLGN Yearly Profit, Operating, Gross MarginsQLGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. QLGN Health Analysis

2.1 Basic Checks

  • QLGN has more shares outstanding than it did 1 year ago.
  • QLGN has more shares outstanding than it did 5 years ago.
  • QLGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
QLGN Yearly Shares OutstandingQLGN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
QLGN Yearly Total Debt VS Total AssetsQLGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • Based on the Altman-Z score of -49.96, we must say that QLGN is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -49.96, QLGN is doing worse than 93.08% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -49.96
ROIC/WACCN/A
WACCN/A
QLGN Yearly LT Debt VS Equity VS FCFQLGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • A Current Ratio of 0.71 indicates that QLGN may have some problems paying its short term obligations.
  • QLGN's Current ratio of 0.71 is on the low side compared to the rest of the industry. QLGN is outperformed by 90.28% of its industry peers.
  • QLGN has a Quick Ratio of 0.71. This is a bad value and indicates that QLGN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of QLGN (0.71) is worse than 90.09% of its industry peers.
Industry RankSector Rank
Current Ratio 0.71
Quick Ratio 0.71
QLGN Yearly Current Assets VS Current LiabilitesQLGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. QLGN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 83.49% over the past year.
  • The Revenue for QLGN has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)83.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.33%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • QLGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.80% yearly.
  • Based on estimates for the next years, QLGN will show a very negative growth in Revenue. The Revenue will decrease by -41.42% on average per year.
EPS Next Y62.96%
EPS Next 2Y31.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

QLGN Yearly Revenue VS EstimatesQLGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 1M 2M 3M 4M 5M
QLGN Yearly EPS VS EstimatesQLGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2021 2022 2023 2024 2025 -50K -100K -150K -200K -250K

More info and screens

Find the best growth stocksShow best growing peers

1

4. QLGN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for QLGN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QLGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QLGN Price Earnings VS Forward Price EarningsQLGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QLGN Per share dataQLGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6 -8

4.3 Compensation for Growth

  • A more expensive valuation may be justified as QLGN's earnings are expected to grow with 31.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.8%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. QLGN Dividend Analysis

5.1 Amount

  • QLGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

QLGN Fundamentals: All Metrics, Ratios and Statistics

QUALIGEN THERAPEUTICS INC

NASDAQ:QLGN (11/18/2025, 8:00:01 PM)

After market: 3.2 -0.01 (-0.31%)

3.21

+0.17 (+5.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner Change78.41%
Ins OwnersN/A
Ins Owner Change0%
Market Cap6.52M
Revenue(TTM)N/A
Net Income(TTM)-7.01M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-8.6
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-3.33
FCFYN/A
OCF(TTM)-3.33
OCFYN/A
SpS0
BVpS-0.81
TBVpS-0.81
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -176.92%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-278.66%
ROA(5y)-298%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.71
Quick Ratio 0.71
Altman-Z -49.96
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.33%
EPS Next Y62.96%
EPS Next 2Y31.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.93%
OCF growth 3YN/A
OCF growth 5YN/A

QUALIGEN THERAPEUTICS INC / QLGN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for QUALIGEN THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 0 / 10 to QLGN.


What is the valuation status for QLGN stock?

ChartMill assigns a valuation rating of 1 / 10 to QUALIGEN THERAPEUTICS INC (QLGN). This can be considered as Overvalued.


How profitable is QUALIGEN THERAPEUTICS INC (QLGN) stock?

QUALIGEN THERAPEUTICS INC (QLGN) has a profitability rating of 0 / 10.


How financially healthy is QUALIGEN THERAPEUTICS INC?

The financial health rating of QUALIGEN THERAPEUTICS INC (QLGN) is 0 / 10.